13F HOLDINGS REPORT (Amended)
ACORN CAPITAL ADVISORS, LLC
Quarter ended Q1 2025 · Filed May 19, 2025 · Accession 0001636587-25-000020
Total Value
$185.8M
Positions
21
Other Managers
0
Confidential Omitted
No
Holdings (21)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | CG ONCOLOGY INC | CGON | 1,131,501 | $32.5M | 17.46% |
| 2 | Y-MABS THERAPEUTICS INC | 984241109 | 2,861,825 | $22.4M | 12.06% |
| 3 | CANDEL THERAPEUTICS INC | CADL | 1,939,644 | $16.8M | 9.06% |
| 4 | UROGEN PHARMA LTD | URGN | 1,516,303 | $16.1M | 8.69% |
| 5 | PUMA BIOTECHNOLOGY INC | PBYI | 3,940,052 | $12.0M | 6.47% |
| 6 | BICARA THERAPEUTICS | BCAX | 643,381 | $11.2M | 6.03% |
| 7 | TERNS PHARMACEUTICALS INC | TERN | 1,971,264 | $10.9M | 5.88% |
| 8 | ONKURE THERAPEUTICS INC | OKUR | 1,439,674 | $10.2M | 5.51% |
| 9 | TREVI THERAPEUTICS INC | TRVI | 2,001,048 | $8.2M | 4.44% |
| 10 | PROTARA THERAPEUTICS INC | TARA | 1,279,800 | $6.8M | 3.64% |
| 11 | CYBIN INC | HELP | 734,393 | $6.5M | 3.49% |
| 12 | CARDIF ONCOLOGY INC | CRDF | 1,442,308 | $6.3M | 3.37% |
| 13 | X4 PHARMACEUTICALS INC | XFOR | 7,310,650 | $5.4M | 2.89% |
| 14 | MURAL ONCOLOGY PLC | G63365103 | 1,286,079 | $4.1M | 2.23% |
| 15 | AADI BIOSCIENCE INC | WHWK | 1,147,052 | $3.6M | 1.95% |
| 16 | OPTINOSE INC | 68404V209 | 422,813 | $2.8M | 1.52% |
| 17 | Q32 BIO INC. | QTTB | 803,425 | $2.8M | 1.49% |
| 18 | ACRIVON THERAPEUTICS INC | ACRV | 405,237 | $2.4M | 1.31% |
| 19 | BIOATLA INC | BCAB | 4,032,046 | $2.4M | 1.28% |
| 20 | VYNE THERAPEUTICS INC | VYNE | 456,970 | $1.5M | 0.82% |
| 21 | VERASTEM INC | VSTM | 779,498 | $779,498 | 0.42% |